Spruce Biosciences
$8.35
43
-$0.15-1.76% Wednesday 20:00
Statistics
Day High
9.29
Day Low
8.06
52W High
45.6
52W Low
4.28
Volume
2,706
Avg. Volume
3,605
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
12MarExpected
Expected EPS
-9.4725
Actual EPS
N/A
Financials
-1,079.94%Profit Margin
Unprofitable4.91MRevenue
-53.04MNet Income
Analyst Ratings
$213.40Average Price Target
The highest estimate is 283.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy 60%
Hold 40%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow SPRBD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Crinetics Pharmaceuticals
CRNX
Mkt Cap4.04B
Neurocrine Biosciences
NBIX
Mkt Cap14.28B
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
AMGEN
AMGN
Mkt Cap160.66B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Ligand Pharmaceuticals
LGND
Mkt Cap3.73B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
About
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Show more...
CEO
Mr. Michael G. Grey
Employees
20
Country
US
Listings
0 Comments
Share your thoughts
FAQ
What is Spruce Biosciences stock price today?▼
The current price of SPRBD is $8.35 USD — it has decreased by -1.76% in the past 24 hours. Watch Spruce Biosciences stock price performance more closely on the chart.
What is Spruce Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Spruce Biosciences stocks are traded under the ticker SPRBD.
What is Spruce Biosciences revenue for the last year?▼
Spruce Biosciences revenue for the last year amounts to 4.91M USD.
What is Spruce Biosciences net income for the last year?▼
SPRBD net income for the last year is -53.04M USD.
How many employees does Spruce Biosciences have?▼
As of April 02, 2026, the company has 20 employees.
In which sector is Spruce Biosciences located?▼
Spruce Biosciences operates in the Health Care sector.
When did Spruce Biosciences complete a stock split?▼
The last stock split for Spruce Biosciences was on August 07, 2025 with a ratio of 1:75.
Where is Spruce Biosciences headquartered?▼
Spruce Biosciences is headquartered in South San Francisco, US.